Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line - PubMed (original) (raw)
Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line
J C Law et al. Leuk Res. 1993 Dec.
Abstract
The K562 human chronic myelogenous leukemia (CML) cell line has attained widespread use as a model for studying hematologic malignancy and erythroid differentiation. Sequencing of the p53 gene in the K562 cell line demonstrated a mutation in exon 5 characterized by a single base insertion (cytosine) between codons 135 and 136. This frameshift mutation leads to an N-terminal truncated protein of 147 amino acids. Only the mutated sequence was present suggesting that the normal allele has been lost. Reverse transcription PCR (RT-PCR) detected a p53 transcript but Western blotting and immunohistochemical staining of cells failed to detect p53 protein. The identification of an inactivation mutation of p53 in the K562 cell line further supports the argument that p53 mutations play a role in myeloid blast transformation of CML.
Similar articles
- p53 in chronic myeloid leukemia cell lines.
Bi S, Hughes T, Bungey J, Chase A, de Fabritiis P, Goldman JM. Bi S, et al. Leukemia. 1992 Aug;6(8):839-42. Leukemia. 1992. PMID: 1640738 - Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.
Hietanen SH, Kurvinen K, Syrjänen K, Grénman S, Carey T, McClatchey K, Syrjänen S. Hietanen SH, et al. Am J Obstet Gynecol. 1995 Nov;173(5):1477-82. doi: 10.1016/0002-9378(95)90636-3. Am J Obstet Gynecol. 1995. PMID: 7503188 - Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.
Gaidano G, Serra A, Guerrasio A, Rege-Cambrin G, Mazza U, Saglio G. Gaidano G, et al. Ann Hematol. 1994 Jan;68(1):3-7. doi: 10.1007/BF01695912. Ann Hematol. 1994. PMID: 8110876 - Role of p53 in leukemogenesis of chronic myeloid leukemia.
Lanza F, Bi S. Lanza F, et al. Stem Cells. 1995 Jul;13(4):445-52. doi: 10.1002/stem.5530130416. Stem Cells. 1995. PMID: 7549904 Review.
Cited by
- Proteomic Analysis Reveals Trilaciclib-Induced Senescence.
Hermosilla-Trespaderne M, Hu-Yang MX, Dannoura A, Frey AM, George AL, Trost M, Marín-Rubio JL. Hermosilla-Trespaderne M, et al. Mol Cell Proteomics. 2024 Jun;23(6):100778. doi: 10.1016/j.mcpro.2024.100778. Epub 2024 Apr 26. Mol Cell Proteomics. 2024. PMID: 38679389 Free PMC article. - FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5.
Takeda K, Ohta S, Nagao M, Kobayashi E, Tago K, Funakoshi-Tago M. Takeda K, et al. Int J Mol Sci. 2024 Mar 26;25(7):3693. doi: 10.3390/ijms25073693. Int J Mol Sci. 2024. PMID: 38612503 Free PMC article. - CX‑5461 potentiates imatinib‑induced apoptosis in K562 cells by stimulating KIF1B expression.
Dai C, Cui X, Wang J, Dong B, Gao H, Cheng M, Jiang F. Dai C, et al. Exp Ther Med. 2024 Jan 18;27(3):107. doi: 10.3892/etm.2024.12395. eCollection 2024 Mar. Exp Ther Med. 2024. PMID: 38356673 Free PMC article. - Anticancer activity features of imidazole-based ionic liquids and lysosomotropic detergents: in silico and in vitro studies.
Gryniukova A, Borysko P, Myziuk I, Alieksieieva D, Hodyna D, Semenyuta I, Kovalishyn V, Metelytsia L, Rogalsky S, Tcherniuk S. Gryniukova A, et al. Mol Divers. 2024 Jan 22. doi: 10.1007/s11030-023-10779-4. Online ahead of print. Mol Divers. 2024. PMID: 38246950 - The Mechanism of Anti-Tumor Activity of 6-Morpholino- and 6-Amino-9-Sulfonylpurine Derivatives on Human Leukemia Cells.
Leventić M, Opačak-Bernardi T, Rastija V, Matić J, Pavlović Saftić D, Ban Ž, Žinić B, Glavaš-Obrovac L. Leventić M, et al. Molecules. 2023 Aug 19;28(16):6136. doi: 10.3390/molecules28166136. Molecules. 2023. PMID: 37630388 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous